Publication:
Improved Tolerance to a New Amino Acid-Based Formula by Infants with Cow's Milk Protein Allergy

dc.contributor.authorPipop Jirapinyoen_US
dc.contributor.authorNarumon Densupsoontornen_US
dc.contributor.authorChannagan Kangwanpornsirien_US
dc.contributor.authorRenu Wongarnen_US
dc.contributor.authorHathaichanok Tirapongpornen_US
dc.contributor.authorKwanjai Chotipanangen_US
dc.contributor.authorPhakkanan Phuangphanen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-11T03:14:02Z
dc.date.accessioned2019-03-14T08:01:53Z
dc.date.available2018-12-11T03:14:02Z
dc.date.available2019-03-14T08:01:53Z
dc.date.issued2016-12-01en_US
dc.description.abstract© 2016 American Society for Parenteral and Enteral Nutrition. Background: Prevalence and severity of cow's milk protein allergy (CMA) in infants are increasing. A proportion of infants with CMA still elicit signs and symptoms of CMA while ingesting commercial amino acid-based formulas (AAFs). We propose that protein in glucose polymers (GPs) derived from corn starch in the AAFs might be the cause of intolerance to AAF in some infants. We thus have produced small molecules of GPs from rice starch, eliminating the protein fraction from them, and subsequently used them as the sole source of carbohydrate in a new amino acid-based formula (NAAF). Methods: The efficacy of the NAAF was compared with that of an AAF in a double-blind, placebo-controlled food challenge (DBPCFC) in young infants with CMA aged <4 months. Infants consumed each formula for 14 days before switching to the other one. If no respiratory, dermatologic, and gastrointestinal symptom occurred, it was considered tolerance. After the challenge, infants consumed the tolerated formula for 4 weeks to prove real tolerance to that formula. Results: Of 46 infants, 23 were intolerant to the AAF, of whom 7 (30.4%) were also intolerant to the NAAF. Sixteen of the 23 infants who were intolerant to the AAF could tolerate the NAAF (P <.05). The minimal important difference of decreasing percentage of intolerance to the NAAF was 34.8% compared with the infants who were intolerant to the AAF. Conclusion: The NAAF is better tolerated than a commercially available AAF for the management of infants with CMA.en_US
dc.identifier.citationNutrition in Clinical Practice. Vol.31, No.6 (2016), 824-828en_US
dc.identifier.doi10.1177/0884533616639108en_US
dc.identifier.issn19412452en_US
dc.identifier.issn08845336en_US
dc.identifier.other2-s2.0-84995769177en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/40947
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84995769177&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleImproved Tolerance to a New Amino Acid-Based Formula by Infants with Cow's Milk Protein Allergyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84995769177&origin=inwarden_US

Files

Collections